Details

Autor(en) / Beteiligte

• Mwakingwe-Omari, Agnes
• Healy, Sara A
• Lane, Jacquelyn
• Cook, David M
• Kalhori, Sahand
• Wyatt, Charles
• Kolluri, Aarti
• Marte-Salcedo, Omely
• Imeru, Alemush
• Nason, Martha
• Ding, Lei K
• Decederfelt, Hope
• Duan, Junhui
• Neal, Jillian
• Raiten, Jacob
• Lee, Grace
• Hume, Jen C C
• Jeon, Jihyun E
• Ikpeama, Ijeoma
• Kc, Natasha
• Chakravarty, Sumana
• Murshedkar, Tooba
• Church, L W Preston
• Manoj, Anita
• Gunasekera, Anusha
• Anderson, Charles
• Murphy, Sean C
• March, Sandra
• Bhatia, Sangeeta N
• James, Eric R
• Billingsley, Peter F
• Sim, B Kim Lee
• Richie, Thomas L
• Zaidi, Irfan
• Hoffman, Stephen L
• Duffy, Patrick E

Titel

Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity

Ist Teil von

• Nature (London), 2021-07, Vol.595 (7866), p.289-294

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• The global decline in malaria has stalled , emphasizing the need for vaccines that induce durable sterilizing immunity. Here we optimized regimens for chemoprophylaxis vaccination (CVac), for which aseptic, purified, cryopreserved, infectious Plasmodium falciparum sporozoites (PfSPZ) were inoculated under prophylactic cover with pyrimethamine (PYR) (Sanaria PfSPZ-CVac(PYR)) or chloroquine (CQ) (PfSPZ-CVac(CQ))-which kill liver-stage and blood-stage parasites, respectively-and we assessed vaccine efficacy against homologous (that is, the same strain as the vaccine) and heterologous (a different strain) controlled human malaria infection (CHMI) three months after immunization ( https://clinicaltrials.gov/ , NCT02511054 and NCT03083847). We report that a fourfold increase in the dose of PfSPZ-CVac(PYR) from 5.12 × 10 to 2 × 10 PfSPZs transformed a minimal vaccine efficacy (low dose, two out of nine (22.2%) participants protected against homologous CHMI), to a high-level vaccine efficacy with seven out of eight (87.5%) individuals protected against homologous and seven out of nine (77.8%) protected against heterologous CHMI. Increased protection was associated with Vδ2 γδ T cell and antibody responses. At the higher dose, PfSPZ-CVac(CQ) protected six out of six (100%) participants against heterologous CHMI three months after immunization. All homologous (four out of four) and heterologous (eight out of eight) infectivity control participants showed parasitaemia. PfSPZ-CVac(CQ) and PfSPZ-CVac(PYR) induced a durable, sterile vaccine efficacy against a heterologous South American strain of P. falciparum, which has a genome and predicted CD8 T cell immunome that differs more strongly from the African vaccine strain than other analysed African P. falciparum strains.